Arena Pharmaceuticals Inc. (ARNA): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Arena Pharmaceuticals ( ARNA) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 1.1%. By the end of trading, Arena Pharmaceuticals fell $0.09 (-1.3%) to $6.86 on average volume. Throughout the day, 6,762,100 shares of Arena Pharmaceuticals exchanged hands as compared to its average daily volume of 5,569,300 shares. The stock ranged in price between $6.82-$7.15 after having opened the day at $7.15 as compared to the previous trading day's close of $6.95. Other companies within the Health Care sector that declined today were: Mast Therapeutics ( MSTX), down 38.6%, Medical Action Industries ( MDCI), down 32.1%, Stereotaxis ( STXS), down 19.9% and Reliv' International ( RELV), down 16.7%.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena Pharmaceuticals has a market cap of $1.5 billion and is part of the drugs industry. Shares are down 22.9% year to date as of the close of trading on Wednesday. Currently there are 3 analysts that rate Arena Pharmaceuticals a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates Arena Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself.

On the positive front, ZELTIQ Aesthetics ( ZLTQ), up 40.2%, Zalicus ( ZLCS), up 30.9%, Biocryst Pharmaceuticals ( BCRX), up 21.1% and Anika Therapeutics ( ANIK), up 20.9% , were all gainers within the health care sector with Celgene Corporation ( CELG) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)

Allergan, USG Corp, Arena Pharmaceuticals: 'Mad Money' Lightning Round

These Stocks Have Changed Direction

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says